University Health Network

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1999-01-01

Employees: 10K

Market Cap: -

Website: http://www.uhn.ca

Clinical Trials

Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Phase 2

Active, not recruiting

Conditions: Advanced Cancer
Ovarian Cancer
Primary Peritoneal Carcinoma
Fallopian Tube Cancer

Interventions: Drug: Pembrolizumab
Biological: DPX-Survivac
Drug: Cyclophosphamide

First Posted Date: 2017-01-24

Last Posted Date: 2024-01-24

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 47

Registration Number: NCT03029403

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Biological: DNT cells

First Posted Date: 2017-01-20

Last Posted Date: 2025-02-03

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 7

Registration Number: NCT03027102

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

PC 360 Survivorship

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Behavioral: Survivorship Care Plan

First Posted Date: 2017-01-11

Last Posted Date: 2023-05-09

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 203

Registration Number: NCT03017456

Locations: 🇨🇦
Vancouver Prostate Centre, Vancouver, British Columbia, Canada
🇨🇦
McGill University Health Centre, Montréal, Quebec, Canada
🇨🇦
University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

Phase 2

Active, not recruiting

Conditions: Endometrial Cancer

Interventions: Drug: Niraparib
Drug: TSR-042

First Posted Date: 2017-01-10

Last Posted Date: 2024-01-30

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 51

Registration Number: NCT03016338

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
London Regional Cancer Centre, London, Ontario, Canada
🇨🇦
Juravinski Cancer Centre, Hamilton, Ontario, Canada

and more 4 locations

Randomized Controlled Trial of Efficacy and Safety of Local Anesthetics and Steroids for Chronic Peripheral Post-traumatic Neuropathic Pain

Phase 3

Completed

Conditions: Neuralgia
Peripheral Neuropathic Pain

Interventions: Drug: Bupivacaine
Other: Saline (Sodium Chloride) solution
Drug: Lidocaine
Drug: Depo-Medrol Injectable Product

First Posted Date: 2017-01-04

Last Posted Date: 2020-03-24

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 3

Registration Number: NCT03009500

Locations: 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada

High Intensity Interval Training for People With Stroke Deficits

Not Applicable

Active, not recruiting

Conditions: Stroke

Interventions: Behavioral: High Intensity Interval Training
Behavioral: Moderate Intensity Continuous Exercise

First Posted Date: 2016-12-30

Last Posted Date: 2023-05-09

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 47

Registration Number: NCT03006731

Locations: 🇨🇦
Toronto Rehabilitation Institute - Rumsey Centre, Toronto, Ontario, Canada

Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity

Phase 1

Withdrawn

Conditions: Squamous Cell Carcinoma, Head And Neck
Resectable Squamous Cell Carcinoma of Oral Cavity
Squamous Cell Carcinoma Mouth

Interventions: Drug: Mocetinostat
Biological: Durvalumab

First Posted Date: 2016-12-15

Last Posted Date: 2017-12-29

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT02993991

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

A Clinical Comparison of Two New Bronchial Blockers vs. Double Lumen Tubes in One Lung Ventilation

Not Applicable

Completed

Conditions: Thoracic Surgery, Lung Isolation

Interventions: Device: Double lumen tube
Device: EZ blocker
Device: Fuji blocker

First Posted Date: 2016-12-06

Last Posted Date: 2021-05-04

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 90

Registration Number: NCT02983149

Locations: 🇨🇦
Toronto General Hospital, 200 Elizabeth St., Toronto, Ontario, Canada

Fecal Calprotectin Levels in Mycophenolate Mofetil Induced Diarrhea and Treatment With Octreotide

Conditions: Immunosuppression
Diarrhea

Interventions: Drug: Octreotide Acetate

First Posted Date: 2016-11-30

Last Posted Date: 2016-11-30

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 10

Registration Number: NCT02977897

Locations: 🇨🇦
Toronto General Hospital, University Health Network, Toronto, Ontario, Canada

FES in Young Children With Perinatal Stroke

Not Applicable

Completed

Conditions: Cerebral Palsy

Interventions: Behavioral: Conventional
Device: FES

First Posted Date: 2016-11-29

Last Posted Date: 2021-09-28

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 10

Registration Number: NCT02975180

Locations: 🇨🇦
Toronto Rehabilitation Institute-University Health Network, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy